The latest news on the results of the 2024 platinib medical insurance negotiations

Pralsetinib (Pralsetinib) is a potent and selective RET receptor tyrosine kinase inhibitor. The ARROW trial was designed to evaluate the efficacy and safety of platinib in patients with advanced solid tumors with RET alterations. Among 23 patients evaluable for efficacy, the overall response rate (primary endpoint) was 57% (95% confidence interval, 35-77). Responses were observed regardless of tumor type or RET fusion partner. The median duration of response, progression-free survival, and overall survival were 12 months, 7 months, and 14 months, respectively. The most common grade ≥3 treatment-related adverse events were neutropenia and anemia. These data validate platinib as a well-tolerated treatment option with rapid, potent, and durable antitumor activity in patients with diverse RET fusion-positive solid tumors.

The original drug Platinib has been launched in China, and the price of 120 pills per box may be around RMB 60,000. Platinib has not yet passed the relevant policies for inclusion in medical insurance. Relevant departments may be conducting medical insurance negotiations. In the future, Platinib is expected to enter the ranks of medical insurance reimbursement. The price of the European version of Platinib's original drug sold overseas may be around RMB 40,000 per box of 60 pills, and the U.S. version may be priced around RMB 150,000 per box (the price may fluctuate due to exchange rates), which is expensive. Generic Platinib drugs are also available for sale overseas. The drug ingredients are basically the same as those of the original drugs at home and abroad. The price of 120 pills per box produced by a Lao pharmaceutical factory may be more than 4,000 yuan (the price may fluctuate due to exchange rate effects).